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Aim: Hypogonadotropic hypogonadism is a production failure of gonadal hormones due to a lack of gonadotropin secretion. Here, we
aimed to determine the prevalence of genomic rearrangements in the KAL1, FGFR1, GPR54, and NELF genes in patients diagnosed
with hypogonadotropic hypogonadism.
Materials and methods: The study included 86 male patients with idiopathic hypogonadotropic hypogonadism (76 diagnosed with
normosmic idiopathic hypogonadotropic hypogonadism and 10 with Kallmann syndrome). Additionally, 95 healthy controls were
recruited to investigate rearrangements in the KAL1, FGFR1, GPR54, and NELF genes, using multiplex ligation dependent probe
amplification.
Results: From the 86 patients, 3 patients with Kallmann syndrome had heterozygous deletions in exon 9 of the KAL1 gene (probe
target sequence: 5941-L05940), and 1 of these patients also had a duplication in exon 11 of the same gene (probe target sequence:
4427-L03813). Additionally, 1 patient with nIHH had a duplication in exons 14 and 18 of the FGFR1 gene (probe target sequences:
4440-L03826 and 4441-L03827, respectively). No deletions/duplications were identified in the GPR54 and NELF genes and no genomic
rearrangement was detected in the control subjects.
Conclusion: To improve our understanding of this complex condition and also for better genetic counseling and directing therapy,
defining the genetic basis of these disorders is essential.
Key words: Normosmic idiopathic hypogonadotropic hypogonadism, Kallmann syndrome, KAL1, FGFR1, GPR54, NELF, multiplex
ligation dependent probe amplification

1. Introduction
Hypogonadism is caused by a lack of gonadal hormone
production. It may be due to inadequate gonadotropin
secretion (hypogonadotropic) or primary testicular failure
(hypergonadotropic). Levels of serum gonadotropin
concentrations in these disorders assist in differential
diagnosis.
Testosterone levels below normal are compatible with
hypergonadotropic hypogonadism if the serum luteinizing
hormone (LH) and follicle-stimulating hormone
(FSH) concentrations are elevated, and the condition is
hypogonadotropic hypogonadism if the serum LH and
FSH concentrations are normal or reduced.
* Correspondence: drmustafacakar@gmail.com
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Kallmann syndrome (KS) is a clinically and genetically
heterogeneous disease. It is associated with idiopathic
hypogonadotropic hypogonadism (IHH), which may be
associated either with anosmia or hyposmia, or with a
normal sense of smell (normosmic hypogonadotropic
hypogonadism, nIHH). Several mutations have been
identified as the underlying cause of the condition to date.
Generally, these are only responsible for the molecular
basis of approximately 10%–20% of all patients with IHH.
These mutations are generally classified into 4 main
groups according to the specific target they affect. Each
of them is characterized by phenotypic and hormonal
variations.
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1. Gonadotropin-releasing hormone (GnRH) neuron
migration and function mutations
2. GnRH synthesis and secretion mutations
3. Hypophyseal response to GnRH mutations
4. Gonadotropin biosynthesis mutations
In this study, we aimed to assess the prevalence
of sequence variations within the genes (including
KAL1, FGFR1, GPR54, and NELF) playing a role in the
pathogenesis of IHH and to determine the association
between genotype and phenotype.
2. Materials and methods
2.1. Patients and controls
The study was conducted between May 2006 and October
2009 at the Department of Endocrinology, Gülhane
Military Medical Academy, Ankara, Turkey. The patients
recruited for the study included 86 males with IHH (76
with nIHH and 10 with KS) and 95 eugonadal males with
the same ethnic origin.
Participants with a chronological age over 18 years and
symptoms of hypogonadism were recruited into the patient
group. They had no history of recent or previously taken
medication and had subnormal testosterone levels with
normal or reduced serum LH and FSH concentrations, a
suppressed gonadotropin response to GnRH stimulation
test, a normal anatomical view of the hypothalamic–
pituitary axis in magnetic resonance imaging (MRI),
and no pathologic finding other than bilateral testicular
atrophy on the scrotal ultrasound. Subjects with a normal
hypothalamo–pituitary–testicular axis were taken into the
control group. All participants were tested in terms of their
olfactory senses. The patient group underwent MRI of the
olfactory bulbs and tracts. Subjects having a decreased
sense of smell or anosmia were accepted as having KS.
Subjects having a normal sense of smell and no evidence
of morphological changes on MRI were accepted as having
nIHH.
After verbal and written instruction about the aim
and procedure of the study, written informed consent
was obtained from all participants before recruitment.
The study was approved by the ethics committee of the
Gülhane Military Medical Academy.
2.2. Biochemical analysis
After venipuncture, blood samples were collected into nonanticoagulated tubes (Grainer, Australia) and centrifuged
at 5000 rpm for 10 min at room temperature. All serum
specimens were stored at –80 °C prior to examination.
A chemiluminescence immunoassay method was
used to determine total testosterone (T), FSH, and LH
levels by using an automated immunoassay analyzer
(E170, Roche, Hitachi Corporation, Osaka, Japan). The
radioimmunoassay kit DSL-4900 (Diagnostic System

Laboratories, Webster, TX, USA) was used to measure free
T levels.
2.3. Genetic analysis
DNA was extracted from the white blood cells of all
patients and controls using the BioRobotGenoVisionGeno
M-6 and EZ1 DNA Blood Kit (QIAGEN, Germany). A
total of 125 ng of DNA in 5 µL units for each multiplex
ligation dependent probe amplification (MLPA) reaction
was used.
2.3.1. DNA denaturation
Five microliters of DNA in 0.2-mL polymerase chain
reaction (PCR) tubes were dissolved in TE (10 mM TrisHCl pH 8.2 + 0.1 mM EDTA). The tubes were put in a
thermocycler, and DNA samples were denatured for 5 min
at 98 °C and immediately cooled to 25 °C before opening
the thermocycler.
2.3.2. Hybridization reaction
A hybridization master mix (1.5 µL MLPA buffer + 1.5 µL
probemix) in quantities of 3 µL was added to each sample
tube and mixed well. The thermocycler program was
continued for 1 min at 95 °C, and then for 16 h at 60 °C.
2.3.3. Ligation reaction
A ligase master mix (3 µL Ligase-65 buffer A + 3 µL
Ligase-65 buffer B + 25 µL dH2O) was added and mixed
well by pipetting gently up and down. Then 1 µL of
Ligase-65 was added and the solution was mixed again.
The thermocycler was paused at 54 °C and 32 µL of the
ligase master mix was added to each reaction tube. The
program was continued for 15 min at 54 °C, followed by 5
min at 98 °C for heat inactivation of the Ligase-65 enzyme,
and then paused at 15 °C.
2.3.4. PCR reaction
A PCR buffer mix (4 µL SALSA PCR buffer + 26 µL dH2O)
was prepared and mixed briefly by turning. Then the 30 µL
of the PCR buffer mix was added to new tubes for the PCR
reaction and 10 µL of each ligation product was transferred
to its corresponding PCR tube at room temperature. A
polymerase master mix (2 µL SALSA PCR primers + 2
µL SALSA enzyme dilution buffer + 5.5 µL dH2O + 0.5
µL SALSA polymerase) was prepared and stored on ice
until use. The thermocycler was heated to 60 °C. The
PCR tubes were placed in it and 10 µL of polymerase mix
was added to each tube. After mixing by pipetting gently
up and down, the thermocycler program was continued
immediately. The thermocycler ran for 35 PCR cycles (30 s
at 95 °C; 30 s at 60 °C; 60 s at 72 °C) and ended with 20 min
of incubation at 72 °C. It was then paused at 15 °C.
2.3.5. Fragment separation
Following the PCR reaction, a mix (0.75 µL of the PCR
reaction + 0.75 µL water + 0.5 µL size standard + 13.5 µL
HiDi formamide) was incubated for 2 min at 94 °C and
stored on ice. PCR products were separated by capillary
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3. Results
The Table shows the hormonal and genetic results of
the patient group. Heterozygous deletions in exon 9 of
the KAL1 gene (probe target sequence: 5941-L05940)
occurred in 3 patients with KS, and 1 of these patients
also had a duplication in exon 11 of the same gene (probe
target sequence: 4427-L03813) (Figures 1–3). One of the
nIHH patients had a duplication in exons 14 and 18 of
the FGFR1 gene (probe target sequences: 4440-L03826
and 4441-L03827, respectively) (Figure 4). No deletions/
duplications were identified in the GPR54 and NELF
genes and no genomic rearrangement was detected in the
control subjects.
In summary, using MLPA for the described genes, 5
genomic rearrangements were present in 4/86 (4.6%)
patients with IHH. If only patients with nIHH were
considered, 1/76 (1.3%) had a previously described
duplication, and if only KS patients were considered, 3/10
(30%) had rearrangements in the KAL1 gene.

electrophoresis using a Beckman Coulter CEQ-8000
Genetic Analyzer.
2.3.6. MLPA Data analysis
The P132 Kallmann-1 kit (MRC Holland, Amsterdam, the
Netherlands) contains MLPA probes for each of the 14
KAL1 exons, and the P133 Kallmann-2 kit (MRC Holland)
contains MLPA probes for most of the exons of the FGFR1
gene (11 of the 18 exons). The P133 Kallmann-2 kit also
contains probes for some of the NELF gene (3 of the 16
exons), the GPR54 gene (3 of the 5 exons), the GnRH1
gene (3 of the 4 exons), and for each of the GnRHR,
PROK2, and PROKR2 genes.
Data were evaluated using Genotyper 2.0 (Applied
Biosystems, Foster City, CA, USA). For the analysis of the
data, Coffalyser software (an Excel-based program) was
used. Peak areas for each exon were converted into an
Excel file and the relative DNA copy number ratios of each
fragment were compared to the same fragments from 2 or
3 healthy subjects.

Table. Hormonal and genetic results of the patient group.
Patient group
P.
No.

Free
testosterone
(pg/mL)

Total
testosterone
(ng/dL)

FSH (mIU/mL)

LH (mIU/mL)

Established
mutations

29

2.30

5.00

0.423

0.100

*Hdel on KAL1.

52

2.05

17.82

0.530

0.160

**Dup on FGFR-1.

81

2.90

48.12

1.080

0.788

***Hdel+Dup on KAL1

84

3.40

49.60

0.476

0.112

*Hdel on KAL1

*Heterozygous deletion on KAL1 gene.
**Heterozygous duplication on FGFR1 gene.
***Heterozygous deletions and duplication on KAL1 gene.
P133 (P52).E07_091123165E
25,000
139.63

20,000
15,000
10,000
5000
Dye Signal
0

0

144.94
401.09
152.35
132.84
189.10
175.99
157.19
228.35
105.50
208.61 243.90
194.62
91.41
170.25
86.0
201.60
162.59
402.03
282.36309.78336.44
182.45 219.50 263.91 300.84
255.30 292.04
100.76
80.09
320.08
381.69 428.45
73.7696.4
346.06374.79 409.30
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Figure 1. Duplication on FGFR1 gene in patient 52: target sequences 4440-L03826 of the
14th and 4441-L03827 of the 18th exons.
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P132 (P29). F04_09112614LX
55,000
50,000
45,000

107.26
134.20
130.93

40,000

246.77

91.56

35,000

219.74
146.55169.77
140.87
157.53183.13
164.21 192.00
282.28
210.04
152.86177.31
201.55
237.97 274.48 308.38
372.97
262.68
115.69
362.06
223.15 251.89 293.01
317.28 354.89 390.54
233.77
302.10
345.63
80.49
328.00
227.47
399.87
337.44
73.94
381.06
61.73
114.69
67.74
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Figure 2. Heterozygous deletion on KAL1 gene in patient 29: target sequence 5941L05940 of the 9th exon.
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Figure 3. Heterozygous deletion on KAL1 gene in patient 81: target sequences 5941L05940 of the 9th and 4427-L03813 of the 11th exons.
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Figure 4. Heterozygous deletion on KAL1 gene in patient 84: target sequence 5941L05940 of 9th exon.
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When the genes are considered separately, KAL1
genomic rearrangements were found in 3/86 (3.4%)
patients with IHH, in 0/76 (0%) patients with nIHH,
and in 3/10 (30%) patients with KS; FGFR1 genomic
rearrangements were found in 1/86 (1.1%) patients with
IHH, in 1/76 (1.3%) patients with nIHH, and in 0/10 (0%)
patients with KS.
4. Discussion
Hypogonadism is a condition resulting from deficient
gonadal functions, with high or low serum gonadotropin
levels due to several reasons. Primary gonadal deficiencies
or pituitary defects may be the causes of this disorder (1).
IHH has been known as a hereditary disease, but studies
pointing towards mutations in 30% of cases lead to a newly
emerging genetic basis of the disease and suggest other genes
to be discovered. KS is a congenital form of IHH and these
patients have absent (anosmia) or diminished (hyposmia)
sense of smell (2). The pathogenetic mechanism depends on
the aplasia or hypoplasia of the olfactory tracts and bulbs (3).
A GnRH deficiency leads to hypogonadism (4), which most
probably results from a failure of the embryonic migration of
neuroendocrine GnRH cells (5). During fetal development,
these cells migrate from the olfactory epithelium to the
hypothalamus (6) and this neuronal movement is modulated
by anosmin, a 680-amino acid neural cell adhesion molecule
encoded by KAL1 (7). Patients with KS may present with
midline craniofacial abnormalities (like cleft palate, cleft
lip, or choanal atresia), involuntary upper limb mirror
movements (bimanual synkinesis), dental or renal agenesis,
sensorineural deafness, oculomotor deficits, and other
less-documented developmental disorders (8). KS is a
genetically heterogeneous disease and males predominantly
have this disorder. The vast majority of cases are sporadic,
but recessive-X-linked, autosomal dominant and autosomal
recessive modes of inheritance have also been described, and
several loss-of-function mutations in different genes have
been identified in this disorder: 1) KAL1 gene mutations on
chromosome Xp22.3, responsible for the X-linked form (9);
2) FGFR1 (KAL2) gene mutations on chromosome 8p11.212; 3) GPR54 gene mutations on chromosome 19p13; and
4) mutations in NELF genes on chromosomes 9q34.3. These
genes are all responsible for the autosomal recessive forms
of the disease (10).
In apparent sporadic forms of IHH, with or without
anosmia, the prevalence of KAL1 mutations has been
variably reported to range from 3.1% to 27.8% (11,12).
Bhagavath et al. reported that the overall KAL1 mutation
prevalence might not be that much higher than previously
estimated. The prevalence reported in 138 IHH patients
(109 males and 29 females) was 3.7% for normosmic
males, 6.3% for anosmic/hyposmic males, and no mutation
was found in female patients (13). In the present study, 3
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of 86 IHH patients (76 with nIHH and 10 with KS) had a
heterozygous deletion in exon 9 of the KAL1 gene (probe
target sequence: 5941-L05940) and 1 of these patients also
carried a duplication in exon 11 of the same gene (probe
target sequence: 4427-L03813). The prevalence of KAL1 gene
mutations was found to be 3.4% among the patient group
(3.9% among the patients with nIHH and 30% among the
patients with KS). This mutation frequency is comparable to
that reported by Bhagavath et al.
In KS, FGFR1 mutation is often due to an autosomal
dominant transition pattern, and hypogonadism may
additionally be associated with cleft palate and dental
agenesia. The degree of hypogonadism and associated
anomalies depends on the incomplete penetration.
Different from KAL1 mutations, FGFR1 mutations have
been identified in patients with hypogonadism that is not
accompanied by anosmia. The genomic defects in patients
with KS are due to tyrosine kinase or single amino acid
change mutations occurring in an immunoglobulin-like
ring. Asp224His and Gly237Asp changes were detected
in the second immunoglobulin-like ring, and Tyr339Cys,
Glu274Gly, and Ser346Cys were changes observed in the
third ring. Gly703Arg, Asn724Lys, and Pro722Ser changes
were detected in the tyrosine kinase region. These mutations
reduce the activity of tyrosine kinase and receptor affinity,
lead to retention of proteins within the endoplasmic
reticulum, and reveal the pathology. This study examined in
detail the FGFR1 copy number variations in hypogonadal
patients and their families. When the study results are
evaluated, the same FGFR1 defect is reported to lead to a
heterogeneous picture with varying degrees of pubertal
development in patients and their family members. This
broad spectrum suggests that many anomalies can be
detected in endogenous GnRH secretion. Genetic defects
in the FGFR1 may take a role in a wide range of disorders,
such as delayed puberty or hypothalamic amenorrhea. In
this study, the close relationship between IHH and dental
anomalies or cleft palate was confirmed in the patient with
FGFR1 duplications, suggesting that FGFR1 plays a key role
in the development of teeth and palate.
Raivio et al. investigated 134 IHH (22 females, 112
males) patients with a normal sense of smell and genotype–
phenotype relationship in terms of FGFR1 gene mutation
frequency, and they evaluated the sequence analysis of the
mentioned gene (14). Heterozygous mutations in the FGFR1
gene occurred in 9 IHH patients (5 men and 4 women, 7%),
and a wide range of clinical features from lack of pubertal
development to reversible IHH was observed in both male
and female patients. An important result of this study was
the higher rate of FGFR1 mutations in the hypogonadal
females.
In the present study, 86 HH patients were scanned
and only 1 patient (numbered 52) had FGFR1 genomic
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rearrangement. There was a duplication on the FGFR1
gene in target sequences 4440-L03826 of the 14th exon and
4441-L03827 of the 18th exon. KS cases due to mutations
of FGFR1 have autosomal dominant penetration, and it is
detected in about 10% of cases. However, our evaluation
of the patient’s family tree failed to show another case with
hypogonadism; the patient was also found to have nIHH.
Pathologies such as renal agenesis and synkinesis are
observed more frequently in cases of KAL1 mutations than
in the genetic form connected to FGFR1. In concordance,
there was no phenotypic abnormality in our patient
associated with FGFR1 gene defect. Understanding the
role of the FGFR1 gene in the human reproductive system
necessitates screening more patients with IHH.
The most commonly used smell identification test
in the literature is the University of Pennsylvania Smell
Identification Test (UPSIT) (15). Clinical assessment of
olfactory function in the study population was achieved
qualitatively by asking the subjects to recognize strong
smells such as coffee, onion, and garlic. Since it is the most
commonly preferred imaging technique, the olfactory
tracts and bulbs of the patients were examined by MRI.
However, MRI images of the olfactory pathways revealed
no abnormalities in hypogonadal patients, including those
with KS. Genetic defects in KS patients were sporadic, and
therefore they had no abnormalities on MRI scans.
The GPR54 gene is also known as AOXR12 or
HOT7T175. It encodes a G-protein-coupled heptahelical
receptor that contains 398 amino acids and shows homology
with the galanin and opioid receptor family (16). De Roux
et al. reported that the GPR54 gene is localized in 19p13
and described a deletion in the GPR54 gene in 5 siblings (4
males, 1 female) with a history of IHH. The deletion was due
to loss of receptor function as a result of a 155-bp deletion
covering the intron 4 3’ and the end of exon 5 to 5’ (17).
Tenenbaum-Rakover et al. reported a homozygous
mutation (T → C transition) in patients with IHH. This
homozygous mutation results in a change of leucine to
proline in position 102. The GPR54 signaling pathway
was inhibited depending on the mutation identified in 5
cases (18). Patients carrying the GPR54 gene mutation
generally have autosomal recessive disease patterns, and the
frequency of the GPR54 mutations varies between 2% and
5% in genetic examination of IHH patients (19). However,
in a study examining 166 patients with IHH by Cerrato et
al., GPR54 gene defects were identified only in 7 patients
and 1 of them showed an autosomal recessive pattern. The
remaining 4 cases were sporadic and a family history could
not be obtained in 3 of them (20). In the present study,
genomic rearrangements of the GPR54 gene were studied
in 86 patients (76 with IHH and 10 with KS), none of whom
had any deletions or duplications. Our study is based on
fragment analysis rather than sequence analysis and only

the presence of copy number variations was investigated.
The GPR54 gene consists of 5 exons, and we could only
investigate 3 exon regions depending on the kit. Both the
method that we used and the low number of patients may be
erroneously interpreted as the cause of failure to detect all
possible rearrangements in this gene.
In mice, the nasal embryonic LHRH factor gene
(NELF) codes for the guidance molecules of olfactory axons
and migration of GnRH neurons. It is equivalent to the
human NELF gene, which is accepted as a new candidate
gene appearing to point to KS. The NELF gene, localized
in 9q34.3, consists of 16 exons and 15 introns. Miura et
al. studied 65 IHH patients (33 with KS) and investigated
the presence of NELF gene mutations. A heterozygous
missense mutation was identified in a sporadic IHH case,
leading to change of alanine to threonine in the 15th exon
and the 480th position (21). Layman et al. investigated 54
IHH/KS patients in terms of KAL1 gene deletions and 100
IHH/KS patients in terms of FGFR1, GNRH1, GNRHR,
GPR54, and NELF gene deletions using the MLPA kit. KAL1
deletions were presented in 7.4% of all patients, and when
only the patients with KS were considered the percentage
increased to 12.1%. Interestingly, no deletion in FGFR1,
GNRH1, GNRHR, GPR54, and NELF genes was detected
in the 100 IHH/KS patients (22). In our study, 10 KS and 76
IHH patients were screened in terms of NELF gene and no
genomic rearrangement was found in the mentioned gene.
MLPA is a new technique and is used effectively in
detecting genomic sequence deletion and duplications
(23). Most of the prevalence studies have used PCR-based
DNA sequencing for detecting point mutations and small
deletions or duplications (23). KAL1 gene deletions were
identified in 4 (7.4%) of 54 patients with IHH (14 with nIHH
and 40 with KS) by Pedersen-White et al., which is nearly a
similar percentage reported by previous studies based on the
traditional PCR-based sequencing methods (23).
In conclusion, numerous genes involved in the maturity
of the hypothalamic–pituitary–gonadal axis have been
identified within the last few years. However, defects in
these genes account for a small minority of cases. These data
suggest that additional genes may play an important role
in the pathogenesis of IHH. Further studies of genes that
regulate hypothalamic–pituitary–gonadal development and
functions are needed to clarify the additional genetic defects.
Finally, MLPA is advantageous over the traditional
techniques because of its simplicity, relatively low cost, and
efficiency for identifying genomic deletions and duplications.
Acknowledgments
The study was supported by the Gülhane Military Medical
Academy Scientific Research Fund (Project No: AR2008/69).

731

BAŞARAN et al. / Turk J Med Sci
References
1.

Akdağ T, Tiftik AM, Sarıyıldız L. A comparative investigation
of anti-Müllerian hormone (AMH) and various biochemical
parameters in patients with cryptorchidism, oligospermia, or
varicocele. Turk J Med Sci 2012; 42: 411–5.

14.

Raivio T, Sidis Y, Plummer L, Chen H, Ma J, Mukherjee A et al.
Impaired fibroblast growth factor receptor 1 signaling as a cause
of normosmic idiopathic hypogonadotropic hypogonadism. J
Clin Endocrinol Metab 2009; 94: 4380–90.

2.

Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects
of primary eunuchoidism. Am J Ment Defic 1944; 48203–36.

15.

3.

De Morsier G. Median craioencephalic dysraphias and
olfactogenital dysplasia. World Neurol 1962; 3485–506.

Doty R, Shaman P, Kimmelman C, Dann M. University of
Pennsylvania Smell Identification Test: a rapid quantitative
olfactory function test for the clinic. Laryngoscope 1984; 94:
176–8.

4.

Naftolin F, Harris G, Bobrow M. Effect of purified luteinizing
hormone releasing factor on normal and hypogonadotrophic
anosmic men. Nature 1971; 232: 496–7.

16.

Lee D, Nguyen T, O’Neill G, Cheng R, Liu Y, Howard A et al.
Discovery of a receptor related to the galanin receptors. FEBS
Lett 1999; 446: 103–7.

5.

Schwanzel-Fukuda M, Bick D, Pfaff D. Luteinizing hormonereleasing hormone (LHRH)-expressing cells do not migrate
normally in an inherited hypogonadal (Kallmann) syndrome.
Brain Res Mol Brain Res 1989; 6: 311–26.

17.

De Roux N, Genin E, Carel J, Matsuda F, Chaussain J, Milgrom
E. Hypogonadotropic hypogonadism due to loss of function of
the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci
USA 2003; 100: 10972–6.

6.

Schwanzel-Fukuda M. Origin and migration of luteinizing
hormone-releasing hormone neurons in mammals. Microsc
Res Tech 1999; 44: 2–10.

18.

7.

González-Martínez D, Kim S, Hu Y, Guimond S, Schofield
J, Winyard P et al. Anosmin-1 modulates fibroblast growth
factor receptor 1 signaling in human gonadotropin-releasing
hormone olfactory neuroblasts through a heparan sulfatedependent mechanism. J Neurosci 2004; 24: 10384–92.

Tenenbaum-Rakover Y, Commenges-Ducos M, Iovane, A,
Aumas C, Admoni O, De Roux N. Neuroendocrine phenotype
analysis in five patients with isolated hypogonadotropic
hypogonadism due to a L102P inactivating mutation of GPR54.
J Clin Endocrinol Metab 2007; 92: 1137–44.

19.

Bianco S, Kaiser U. The genetic and molecular basis of idiopathic
hypogonadotropic hypogonadism. Nat Rev Endocrinol 2009;
5: 569–76.

20.

Cerrato F, Shagoury J, Kralickova M, Dwyer A, Falardeau
J, Ozata M et al. Coding sequence analysis of GNRHR and
GPR54 in patients with congenital and adult-onset forms of
hypogonadotropic hypogonadism. Eur J Endocrinol 2006; 155:
S3–S10.

21.

Miura K, Acierno JJ, Seminara S. Characterization of the
human nasal embryonic LHRH factor gene, NELF, and
a mutation screening among 65 patients with idiopathic
hypogonadotropic hypogonadism (IHH). J Hum Genet 2004;
49: 265–8.

22.

Pedersen-White J, Chorich L, Bick D, Sherins R, Layman L. The
prevalence of intragenic deletions in patients with idiopathic
hypogonadotropic hypogonadism and Kallmann syndrome.
Mol Hum Reprod 2008; 14: 367–70.

23.

Schouten J, McElgunn C, Waaijer R, Zwijnenburg D, Diepvens
F, Pals G. Relative quantification of 40 nucleic acid sequences
by multiplex ligation-dependent probe amplification. Nucleic
Acids Res 2002; 30: e57.

8.

Tsai P, Gill J. Mechanisms of disease: insights into X-linked
and autosomal-dominant Kallmann syndrome. Nat Clin Pract
Endocrinol Metab 2006; 2: 160–71.

9.

Hardelin J, Levilliers J, Castillo I del, Cohen-Salmon M,
Legouis R, Blanchard S et al. X chromosome-linked Kallmann
syndrome: stop mutations validate the candidate gene. Proc
Natl Acad Sci USA 1992; 89: 8190–4.

10.

11.

Dodé C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler
M et al. Kallmann syndrome: mutations in the genes encoding
prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006;
2: 175.
Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N,
Kawakita S et al. Clinical assessment and mutation analysis
of Kallmann syndrome 1 (KAL1) and fibroblast growth factor
receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic
patients. J Clin Endocrinol Metab 2004; 89: 1079–88.

12.

Albuisson J, Pêcheux C, Carel J, Lacombe D, Leheup B,
Lapuzina P et al. Kallmann syndrome: 14 novel mutations in
KAL1 and FGFR1 (KAL2). Hum Mutat 2005; 25: 98–9.

13.

Bhagavath B, Xu N, Ozata M, Rosenfield R, Bick D, Sherins R
et al. KAL1 mutations are not a common cause of idiopathic
hypogonadotrophic hypogonadism in humans. Mol Hum
Reprod 2007; 13: 165–70.

732

